# Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer

> **NCT01826396** · PHASE2 · UNKNOWN · sponsor: **Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences** · enrollment: 100 (estimated)

## Conditions studied

- Colonic Neoplasms

## Interventions

- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01826396
- **Lead sponsor:** Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2013-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01826396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01826396, "Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01826396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*